Using ASO-PCR assay to detect JAK2V617F mutation in 42 patient with Polycythemia vera (PV), 57 patient with Essential thrombocythemia (ET) from 5/2011 to 10/2012 showed that: 85,71 percent patients with PV and 66,67 percent patients with ET expressing JAK2V617F mutation
hemoglobin concentration, WBC of ET patient with JAK2V617F( +) higher than patient JAK2 V617F (-)
platelets of PV patient with JAK2V617F (+) higher than patient JAK2 V617F (-).